

REMARKS

In the Office action, claims directed to the following patentably distinct species involving treatment with IFN- τ to lower elevated IFN- γ were identified. The species include:

Species 1. An autoimmune disease (claims 4-6).

Species 2. Administration of IFN- α or IFN- β (claims 7-10) wherein the treatment population is:

- a. not further specified and treated with IFN- β (claim 8)
- b. MS and treated with IFN- β (claim 8)
- c. virally infected and treated with IFN- α (claim 9)
- d. suffering from a cellular proliferative condition and treated with an antiproliferative agent or IFN- α (claim 10)

Species 3. An unspecified disease condition.

In response, the applicants elect Species 1, without traverse. Pending claims 1-6 read on the elected species. Claims 7-11 are withdrawn as being drawn to a non-elected species.

Claims 1, 4, 6, 7, and 9-10 are generic, and it is Applicants' understanding that upon allowance of a generic claim, non-elected species will be considered.

No fees are believed due with this communication. However, the Commissioner is hereby authorized and requested to charge any deficiency in fees herein to Deposit Account No. 50-2207.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned at (650) 838-4402.

Respectfully submitted,
Perkins Coie LLP

Date: 12.29.06

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:
Customer No. 22918